A Randomized, Parallel-Group, Open-Label Study to Evaluate the Absolute Bioavailability, Pharmacokinetics, Tolerability and Safety of a High Concentration Formulation of Belimumab (HGS1006), a Fully Human Monoclonal Anti-BLyS Antibody, Administered Subcutaneously to Healthy Subjects

Trial Profile

A Randomized, Parallel-Group, Open-Label Study to Evaluate the Absolute Bioavailability, Pharmacokinetics, Tolerability and Safety of a High Concentration Formulation of Belimumab (HGS1006), a Fully Human Monoclonal Anti-BLyS Antibody, Administered Subcutaneously to Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Belimumab (Primary) ; Belimumab (Primary)
  • Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis; Lupus nephritis; Membranous glomerulonephritis; Myasthenia gravis; Myositis; Renal transplant rejection; Sjogren's syndrome; Systemic lupus erythematosus; Systemic scleroderma
  • Focus Pharmacokinetics
  • Sponsors Human Genome Sciences
  • Most Recent Events

    • 30 Jan 2013 Trial association changed from Human Genome Sciences to GlaxoSmithKline, as Human Genome Sciences acquired by GlaxoSmithKline.
    • 14 Nov 2012 Results presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology Health Professionals.
    • 30 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top